Cancer Chemotherapy and Pharmacology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors
ConclusionsThis study supports the tolerability of 20  mg lenvatinib/day plus 200 mg pembrolizumab every 3 weeks in Japanese patients, consistent with the results from a global study of lenvatinib plus pembrolizumab combination therapy in patients with selected solid tumors. Favorable antitumor activity was observed and there were no new safety sign als identified.Trial registration Clinical Trials.gov number: NCT03006887. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 26, 2022 Category: Cancer & Oncology Source Type: research

Absorption, distribution, metabolism, and excretion of [14C]Mefuparib (CVL218), a novel PARP1/2 inhibitor, in rats
ConclusionsCVL218 is a fast-metabolizing drug and is mainly excreted in feces. TheB/P ratio prediction and observation data for CVL218 were consistent. Furthermore, theKp,uu,brain value indicated that penetration through the BBB might be mediated by uptake transporters. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 25, 2022 Category: Cancer & Oncology Source Type: research

Starting dose selection of palbociclib in Chinese patients with breast cancer based on population kinetic –pharmacodynamic model of neutropenia
AbstractNeutropenia is the most common adverse event (AE) of palbociclib, an oral CDK4/6 inhibitor for breast cancer. Neutropenia increases the risk of infection and is even life threatening. Asian patients generally suffer more severe neutropenia from palbociclib treatment, but the label does not recommend a reduction in the starting dose for Asian patients. Therefore, the study aimed to explore the exposure –response (E–R) relationship in Chinese patients and preliminarily generate a scale for starting dose selection of palbociclib in Chinese patients. After comparing the kinetic–pharmacodynamic (K–PD) and the ph...
Source: Cancer Chemotherapy and Pharmacology - October 22, 2022 Category: Cancer & Oncology Source Type: research

Mass spectroscopy-based proteomics and metabolomics analysis of triple-positive breast cancer cells treated with tamoxifen and/or trastuzumab
ConclusionOur findings in protein and metabolite level research revealed that anti-cancer drug therapy had a significant impact on the key signalling pathways and molecular processes in triple positive BT-474 cell lines.Graphical abstract (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 20, 2022 Category: Cancer & Oncology Source Type: research

Disulfiram enhances chemotherapeutic effects of doxorubicin liposomes against human hepatocellular carcinoma via activating ROS-induced cell stress response pathways
ConclusionsDue to its low price and good safety, it is worth to repurposing disulfiram as a chemotherapeutic drug. Furthermore, MDM4 may act as a biomarker for observation the clinical effect of disulfiram-based treatment. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 17, 2022 Category: Cancer & Oncology Source Type: research

A prospective, open-label, randomised, parallel design study of 4 generic formulations of intramuscular L-asparaginase in childhood precursor B-cell acute lymphoblastic leukaemia (ALL)
Conclusion Generic A and B had better trough asparaginase activity compared to Generic D and C. Overall, generic formulations had lower asparaginase activity which raises serious clinical concerns regarding their quality. Until strict regulatory enforcement improves the quality of these generics, dose adaptive approaches coupled with therapeutic drug monitoring need to be considered. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 17, 2022 Category: Cancer & Oncology Source Type: research

An inhibitor of BRD4, GNE987, inhibits the growth of glioblastoma cells by targeting C-Myc and S100A16
ConclusionGNE987 may be effective against GBM that targets C-Myc expression and influences S100A16 transcription through downregulation of BRD4. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 12, 2022 Category: Cancer & Oncology Source Type: research

Effects of vitamin E in preventing taxane ‑induced peripheral neuropathy
(Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 5, 2022 Category: Cancer & Oncology Source Type: research

The use of vitamin E in preventing taxane ‐induced peripheral neuropathy
(Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 5, 2022 Category: Cancer & Oncology Source Type: research

Distribution of therapeutic monoclonal antibodies into ascites in advanced gastric cancer patients with peritoneal metastasis: case reports and literature review
ConclusionOur results suggest that therapeutic monoclonal antibodies, including ramucirumab and nivolumab, are distributed into massive ascites in AGC patients concomitantly with endogenous IgG. In these patients, retention of ascites and its removal may result in decreased systemic drug exposure to ramucirumab and nivolumab. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - September 30, 2022 Category: Cancer & Oncology Source Type: research

Idiopathic hyperammonemic encephalopathy secondary to gemcitabine –cisplatin treatment
We present a case following treatment with gemcitabine –cisplatin in a patient with cholangiocarcinoma. The etiology of chemotherapy-induced idiopathic hyperammonemic encephalopathy remains unclear and existing theories differ per chemotherapeutic agent. Physicians treating patients with gemcitabine–cisplatin should be aware of the possibility of th is complication, especially because it is treatable when recognized early. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - September 20, 2022 Category: Cancer & Oncology Source Type: research

The effect of rifampin on the pharmacokinetics of famitinib in healthy subjects
ConclusionCo-administration of rifampin considerably reduces plasma concentration of famitinb due to CYP3A4 induction. Concomitant administration of famitinib and strong CYP3A4 inducers should be avoided, whereas when simultaneous use with inducers of CYP3A4, dose adjustment of famitinb is recommended.Clinical trial registration numberNCT04494659 (July 31, 2020). (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - September 15, 2022 Category: Cancer & Oncology Source Type: research

Population pharmacokinetics of zanidatamab, an anti-HER2 biparatopic antibody, in patients with advanced or metastatic cancer
ConclusionThe identified significant covariates were not considered clinically meaningful. Both weight-based (30  mg/kg Q3W) and two-tiered flat dosing (1800/2400 mg Q3W, 70 kg threshold) strategies are expected to provide similar exposures of zanidatamab. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - September 14, 2022 Category: Cancer & Oncology Source Type: research

Re-thinking the possible interaction between proton pump inhibitors and capecitabine
AbstractProton Pump Inhibitors (PPI) rank within the top ten most prescribed medications in Europe and USA. A high frequency of PPI use has been reported amongst patients undergoing chemotherapy, to mitigate treatment-induced gastritis or gastro-oesophageal reflux. Several recent, mostly retrospective, observational studies have reported inferior survival outcomes among patients on capecitabine who concomitantly use PPI. Whilst this association is yet to be definitively established, given the prominence of capecitabine as an anti-cancer treatment with multiple indications, these reports have raised concern within the oncol...
Source: Cancer Chemotherapy and Pharmacology - September 13, 2022 Category: Cancer & Oncology Source Type: research

Introducing a simple and cost-effective RT-PCR protocol for detection of DPYD*2A polymorphism: the first study in Kurdish population
ConclusionThis was the first study that detectDPYD*2A polymorphism in the Kurdish population. Our method was successfully able to detect theDPYD*2A variant and, due to its simplicity and cost-effectiveness, it may be considered as an alternative to the current methods, especially in developing countries. Our detected polymorphism rate at 0.8% is comparable with other studies. Despite the low rate ofDPYD*2A polymorphism, pharmacogenetics assessment before beginning the treatment process is highly recommended due to its association with a high risk of severe toxicity. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - September 9, 2022 Category: Cancer & Oncology Source Type: research